AKT1 and prostate carcinoma: Notably, experimentally validated pathways included the PI3K-AKT signaling pathway, where MYC plays a central role, and the JAK-STAT signaling pathway involved STAT3. An in-vitro study on prostate cancer cells exposed to PI3K/mToR inhibitors found to trigger radio-sensitization in the associated PI3K/mToR pathway [67].